Mobile

A Phase III, randomised, double blind, placebo controlled study to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymorphic light erupt...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-010843-15

A Phase III, randomised, double blind, placebo controlled study to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymorphic light eruption (PLE)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary objective To determine whether afamelanotide can reduce the severity of outbreaks of PLE.

Critère d'inclusion

  • Polymorphic light eruption (PLE)

Liens